Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

By W. Weng, R. Levy. Journal of Clinical Oncology, 2003

1,369 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ab9482ee41b4912f0c0a66950bf59e4821331e8e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. A. Chan
2. D. Baty
3. T. Friess
4. Lloyd J. Old
5. M. H. V. Van Regenmortel
6. Etienne Weiss
7. J. Ravetch
8. P. Carter

In Pathology and Forensic Medicine

1. D. Baty
2. M. H. V. Van Regenmortel
3. Etienne Weiss
4. J. Ravetch
5. P. Carter
6. F. Nimmerjahn
7. P. Chames
8. M. Pescovitz

In Radiology, Nuclear Medicine and Imaging

1. F. Nimmerjahn
2. J. Ravetch
3. A. Chan
4. D. Baty
5. M. H. V. Van Regenmortel
6. Etienne Weiss
7. P. Carter
8. P. Chames

Citations in the corpus

• The broad spectrum of human natural killer cell diversity (2017, background): “Moreover, from the ground-breaking translational work of Velardi, Ravetch, Levy, and several other scientists, it is clear that human NK cell effector function has a critical role in the direct elimination of malignancy (Clynes et al., 2000; Ruggeri et al., 2002; Weng and Levy, 2003).”
• Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors (2011, background): “activating FcgR, cancer therapeutic Abs lose their effect on tumor growth (30), and in cancer patients FcgR polymorphisms directly impact therapeutic responses to Abs (31, 42, 43).”
• Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1 (2005, background): “Rituximab-treated NHL patients that express the high affinity allele of Fc RIIIA (V158) have better prognostic outcomes than patients that solely express the low affinity allele of Fc RIIIA (F158) (36, 37).”
• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. (2010, background): “Rituximab therapy of follicular lymphoma patients homozygous for the high-affinity allele is associated with significantly higher response rates and progression-free survival.(33,34) Similar studies have found the same correlation for other IgG1 antibodies, including trastuzumab in the treatment of ”
• Potent antibody therapeutics by design (2006, background): “The strongest evidence for an Fc-mediated contribution to antibody efficacy in patients is for rituximab: responsiveness to rituximab in patients with non-Hodgkin's lymphoma correlates with polymorphisms in FcγRIIIa”
• The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy (2004, background): “Consistent with an essential role for macrophages in B cell depletion after anti-CD20 mAb treatment, responses to Rituximab therapy also correlate with polymorphisms in human Fc RIIa, which is only expressed on macrophages and DCs (59).”
• Antibody therapy of cancer (2012, background): “ADCC has been demonstrated to have a major role in antibody efficacy, and there is evidence that FcγRIIa-131H polymorphisms have a favourable effect on response rates for cetuximab in colorectal cancer, trastuzumab in breast cancer and rituximab in follicular lymphom”